Mission Therapeutics @MISSIONTherapeu, a drug discovery company focused on selectively inhibiting deubiquitylating enzymes (DUBs), raised $15m (£12m) in a round led by Pfizer Ventures, the venture capital arm of @Pfizer $PFE

https://t.co/kvWujlvQ2Q https://t.co/hV4IemB1c5